Circulating Tumor DNA as a Prognostic Marker in Stage III Colon Cancer-Reply

Jeanne Tie^{1

2

3

4}, Bert Vogelstein⁵, Peter Gibbs^{1

2

4}

Affiliations

¹ Division of Personalised Oncology, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
² Department of Medical Oncology, Western Health, Melbourne, Victoria, Australia.
³ Department of Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
⁴ Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Victoria, Australia.
⁵ Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Comment

Jeanne Tie et al. JAMA Oncol. 2020.

. 2020 Jun 1;6(6):932-933.

doi: 10.1001/jamaoncol.2020.0289.

Jeanne Tie^{1

2

3

4}, Bert Vogelstein⁵, Peter Gibbs^{1

2

4}

¹ Division of Personalised Oncology, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
² Department of Medical Oncology, Western Health, Melbourne, Victoria, Australia.
³ Department of Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
⁴ Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Victoria, Australia.
⁵ Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University School of Medicine, Baltimore, Maryland.

No abstract available

Comment on

Circulating Tumor DNA as a Prognostic Marker in Stage III Colon Cancer.
Zhao Z, Cai S, Wang Z. Zhao Z, et al. JAMA Oncol. 2020 Jun 1;6(6):932. doi: 10.1001/jamaoncol.2020.0283. JAMA Oncol. 2020. PMID: 32239189 No abstract available.